Diabetes Drug Wins in HFrEF; Swift Shift to TAVR; Neurologists to Tackle HTN? - MedPage Today
Diabetes Drug Wins in HFrEF; Swift Shift to TAVR; Neurologists to Tackle HTN? MedPage Today
The SGLT2 diabetes drug dapagliflozin (Farxiga) significantly reduced cardiovascular death and worsening of heart failure with reduced ejection fraction in ...
Comments
Post a Comment